Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance

Novavax IncTrade
Vanguard Emerging Markets Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.4. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

NVAXVWO
Market Cap
$1.31B
Sector
Health
52-Week High
$11.19$61.24
52-Week Low
$6.22$51.20
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Vanguard Emerging Markets Stock Index Fund ETF

VWO, the Vanguard FTSE Emerging Markets ETF, trades at $60.41, up 0.13% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The fund's low expense ratio of 0.06% and focus on emerging markets attract institutional inflows, as seen in recent 13F filings. Recent news highlights strong capital flows into emerging market ETFs and comparisons with peers on cost and diversification.

The outlook for VWO is supported by record inflows and favorable expense ratios, but risks include concentrated exposure to developing economies and currency volatility. Analyst sentiment is generally positive due to diversification benefits and cost efficiency, though geopolitical and economic uncertainties in emerging markets pose significant headwinds for sustained growth.

Returns comparison

Trailing returns across standard periods

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Vanguard Emerging Markets Stock Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.

Read more on VWO